Telix Pharmaceuticals Ltd (ASX:TLX) is a biopharmaceutical company focused on developing diagnostic and therapeutic products using molecularly targeted radiation. The company operates in the healthcare sector, competing with other biotech firms in the field of radiopharmaceuticals. On January 19, 2026, RBC Capital upgraded TLX's stock grade to "Outperform" from "Sector Perform," with the stock priced at $99.03, as highlighted by StreetInsider.
The upgrade by RBC Capital suggests confidence in Telix's future performance. This is similar to the situation with AngloGold Ashanti PLC (NYSE:AU), which has received a "Moderate Buy" consensus from eight brokerages. Despite one analyst rating AU as a sell, six have issued a buy rating, indicating positive sentiment towards the stock.
AngloGold Ashanti's stock has seen varied analyst opinions, with Zacks Research downgrading it from "strong-buy" to "hold," while Scotiabank raised its target price from $90.00 to $92.00, giving it a "sector outperform" rating. Wall Street Zen also upgraded AU from "hold" to "buy," reflecting a mixed but generally optimistic outlook.
Currently, AU is trading at $99.03 on the NYSE, with a slight increase of $0.48 or 0.49% from the previous session. The stock has fluctuated between $95.64 and $99.30 today, and over the past year, it has ranged from a low of $27.44 to a high of $100.31. AngloGold Ashanti's market capitalization is approximately $50 billion, with a trading volume of 2,311,549 shares.
